GSK
875 hedge funds and large institutions have $12B invested in GSK in 2024 Q2 according to their latest regulatory filings, with 75 funds opening new positions, 307 increasing their positions, 302 reducing their positions, and 86 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
875
Holders Change
-28
Holders Change %
-3.1%
% of All Funds
12.73%
Holding in Top 10
10
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-28.57%
% of All Funds
0.15%
New
75
Increased
307
Reduced
302
Closed
86
Calls
$172M
Puts
$109M
Net Calls
+$63.4M
Net Calls Change
-$22.8M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$84.8M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$80.8M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$78.5M |
| 4 |
Primecap Management
Pasadena,
California
|
+$68.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$67.1M |
Top Sellers
| 1 |
Holocene Advisors
New York
|
-$117M |
| 2 |
Morgan Stanley
New York
|
-$91M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$70.8M |
| 4 |
Citigroup
New York
|
-$67.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$55.9M |
